The primary objective of the study was to evaluate the effect of a hydrolyzed polysaccharide, Rice Bran Arabinoxylan Compound (RBAC), on biomarkers in adults with nonalcoholic fatty liver disease ...(NAFLD). A 90-day randomized double-blind placebo-controlled trial examined the effect of RBAC on complete blood count, liver enzymes, lipids, oxidative stress markers, cytokines, and growth factors. Twenty-three adults with NAFLD were enrolled and randomly assigned to one of the two study conditions (n = 12 RBAC and n = 11 placebo) and consumed 1 gram/day of either compound for 90 days. Subjects were assessed at baseline and 45 and 90 days. No adverse effects were reported. Alkaline phosphatase significantly decreased (−3.1%; SD = 19.9; F1, 19 = 5.1, p=0.03) in the RBAC group compared to placebo. Percent monocytes (17.9%; SD = 18.3; F1, 19 = 5.9, p=0.02) and percent eosinophils (30.6%; SD = 30.5; F1, 19 = 12.3, p<0.01) increased in the RBAC group. IFN-γ (156%; SD = 131.8; F1, 19 = 4.2, p=0.06) and IL-18 (29.1%; SD = 64; F1, 19 = 5.3, p=0.03) increased in the RBAC group compared to placebo. Other improvements were noted for platelets, neutrophils, neutrophil-lymphocyte ratio, γ-glutamyl transferase, and 4-hydroxynonenal. RBAC had beneficial effects on several biomarkers that add to the known immunomodulatory activities of RBAC, which may be promising for people with NAFLD. This trial is registered with NCT02568787.
The primary objective of the study was to evaluate the effect of a hydrolyzed polysaccharide, Rice Bran Arabinoxylan Compound (RBAC), on biomarkers in adults with nonalcoholic fatty liver disease ...(NAFLD). A 90-day randomized double-blind placebo-controlled trial examined the effect of RBAC on complete blood count, liver enzymes, lipids, oxidative stress markers, cytokines, and growth factors. Twenty-three adults with NAFLD were enrolled and randomly assigned to one of the two study conditions (n=12 RBAC and n=11 placebo) and consumed 1 gram/day of either compound for 90 days. Subjects were assessed at baseline and 45 and 90 days. No adverse effects were reported. Alkaline phosphatase significantly decreased (−3.1%; SD=19.9; F1,19=5.1, p=0.03) in the RBAC group compared to the placebo group. The percentages of monocytes (17.9%; SD=18.3; F1,19=5.9, p=0.02) and eosinophils (30.6%; SD=30.5; F1,19=12.3, p<0.01) increased in the RBAC group. IFN-γ (156%; SD=131.8; F1,19=4.2, p=0.06) and IL-18 (29.1%; SD=64; F1,19=5.3, p=0.03) increased in the RBAC group compared to the placebo group. Other improvements were noted for platelets, neutrophils, neutrophil-lymphocyte ratio, γ-glutamyl transferase, and 4-hydroxynonenal. RBAC had beneficial effects on several biomarkers that adds to the known immunomodulatory activities of RBAC, which may be promising for people with NAFLD.
Multiple sclerosis (MS) is a progressive neurodegenerative disease associated with increased infection rates, chronic inflammation, and premature death. Optimization of nutritional status via dietary ...supplementation may improve immune function in people suffering from MS and lead to decreased rates of infection. Fifteen individuals with a diagnosis of relapsing-remitting MS for an average of 12.4 years (SD =7.4; R = 2, 25) were enrolled in a one-year open-label clinical trial. Participants consumed a broad-spectrum dietary supplement regimen containing polysaccharides, phytochemicals, antioxidants, vitamins, and minerals three times per day. The occurrence of infections and a panel of cytokines, growth factors, and T- and B-cell subsets were assessed at baseline and 12 months. Seven female and 8 male participants with an average age of 51.3 years (SD =7.2; R = 38, 65) completed the study. At the end of the intervention, participants had fewer total infections (M = 7.9, SD =8.1 at baseline and M = 2.5, SD =4.3 at 12-month follow-up). At 12 months, IL-2, TNF-α, EGF, and CD95 + CD34+ significantly increased, while IL-1β significantly decreased. No major adverse effects were reported; only mild gastrointestinal intolerance was reported in four cases. A decreased occurrence of infection was observed in MS patients treated with 12 months of a polysaccharide-based multinutrient dietary supplement. Significant changes were also noted in several key biomarkers that would be physiologically favorable to the MS population. Thus, the results of this study suggest an immunomodulatory effect of the dietary supplement regimen studied.
Multiple sclerosis (MS) is a progressive neurodegenerative disease that exerts a significant quality-of-life toll on patients. According to the literature, broad-spectrum dietary supplementation ...including a variety of nutrients, polysaccharides, and compounds may improve the quality of life, functionality, and symptom severity in people with MS. Individuals (n = 15) diagnosed with relapsing-remitting MS (RRMS) for an average of 12.4 years (SD = 7.4; R = 2, 25) were enrolled in a one-year open-label clinical trial in which they consumed a broad-spectrum dietary supplement regimen three times daily. Participants were assessed at baseline and at 3, 6, 9, and 12 months with the following: (1) Functional Assessment of MS (FAMS), (2) the EQ-5D-3L, (3) Beck Depression Inventory-II (BDI), (4) Health Conditions Discomfort Scale (HCDS), and (5) Self-Assessment of Severity of MS Symptoms Scale (SASMSSS). Participants included seven females and eight males (M age = 51.3 years; SD = 7.2; R = 38, 65). Few minor gastrointestinal effects were reported. At the end of the intervention, participants showed significant improvements in all outcome measures, particularly functionality on the FAMS, overall quality of life on the EQ-5D-3L, fewer depressive symptoms on the BDI, and improved severity of symptoms on the HCDS and the SASMSSS. Our results suggest that dietary supplementation containing a variety of nutrients can improve the quality of life, severity of disease symptoms, and functionality in MS patients. These findings are clinically promising for MS patients, given the lack of treatment options geared toward improving quality of life in this population.
The primary objective of the study was to evaluate the effects of a hydrolyzed polysaccharide, rice bran arabinoxylan compound (RBAC), on immune, hepatic, and renal function in HIV + individuals. A ...six-month randomized double-blind placebo-controlled trial was utilized to conduct the intervention. Forty-seven HIV + participants on stable antiretroviral therapy were enrolled and randomly assigned to one of the two study conditions (n = 22 RBAC and n = 25 placebo) and consumed 3 gram/day of either compound for six months. Participants were assessed at baseline and 3 and 6 months follow-up for CD4+ and CD8+, liver enzymes, and kidney function. No side effects were reported, and liver and kidney markers nearly remained completely within normal limits. The percentage change in CD4+ was similar for the placebo (+2.2%) and RBAC (+3.1%) groups at 6 months follow-up. The percentage change in CD8+ count significantly decreased from baseline to 6 months in the RBAC group (−5.2%), whereas it increased in the placebo group (+57.8%; p = 0.04). The CD4+/CD8+ ratio improved clinically in the RBAC group from 0.95 (SD =0.62) at baseline to 1.07 (SD =0.11) at 6 months, whereas it declined in the placebo group from 0.96 (SD =0.80) at baseline to 0.72 (SD =0.59) at 6 months. Our results showed a statistically significant decrease in CD8+ count and a clinically significant increase in CD4+/CD8+ ratio for the RBAC group compared to the placebo group. Thus, the results of this study suggest that the immunomodulatory and antisenescent activities of RBAC are promising for the HIV population.
The primary objective of the study was to evaluate the effects of a hydrolyzed polysaccharide, rice bran arabinoxylan compound (RBAC), on immune, hepatic, and renal function in HIV + individuals. A ...6-month randomized double-blind placebo-controlled trial was utilized to conduct the intervention. Forty-seven HIV + individuals on stable antiretroviral therapy were enrolled and randomly assigned to one of the 2 study conditions (n = 22 RBAC and n = 25 placebo) and consumed 3 gram/day of either compound for 6 months. Participants were assessed at baseline and 3 and 6 months follow-up for CD4+ and CD8+, liver enzymes, and kidney function. No side effects were reported, and liver and kidney markers remained nearly completely within normal limits. The percentage change in CD4+ was similar for the placebo (+2.2%) and RBAC (+3.1%) groups at 6 months follow-up. The percentage change in CD8+ count significantly decreased from baseline to 6 months in the RBAC group (−5.2%), whereas it increased in the placebo group (+57.8%; p = 0.04). The CD4+/CD8+ ratio improved clinically in the RBAC group from 0.95 (SD = 0.62) at baseline to 1.07 (SD = 0.11) at 6 months, whereas it declined in the placebo group from 0.96 (SD = 0.80) at baseline to 0.72 (SD = 0.59) at 6 months. Our results showed a statistically significant decrease in CD8+ count and a clinically significant increase in CD4+/CD8+ ratio for the RBAC group compared to the placebo group. Thus, the results of this study suggest that the immunomodulatory and antisenescent activities of RBAC are promising for the HIV population.
Given the ongoing problems of hypertension and endothelial dysfunction in the HIV population, the primary objective of the study was to assess the cardiovascular, endothelial function, and immune ...markers in response to rice bran arabinoxylan compound (RBAC) treatment in a sample of HIV
adults on antiretroviral therapy (ART).
A randomized, double-blind placebo-controlled trial of 6 months was used to execute the study.
Forty-seven subjects were enrolled and randomly assigned to one of two study conditions (
=22 RBAC and
=25 placebo) for 6 months with assessments at baseline and 3 and 6 months. A multivariate repeated measures analysis of variance model was used to assess the differences between RBAC and placebo groups in cardiovascular (systolic blood pressure), endothelial function (skin blood flow in response to nitric oxide), and immune (CD4
cell count) markers from baseline to 6 months.
The effect of treatment (RBAC versus placebo) was significant (Wilks' λ=0.92, F3, 102=3.07,
=0.03). The effect of time was significant (Wilks' λ=0.10, F2, 103=474.6,
<0.001). The overall interaction between treatment and time was significant (Wilks' λ=0.92, F2, 103=4.58,
=0.01). Time contrasts showed that a difference in the overall dependent variable did not occur from baseline to 3 months (F1, 104=2.7,
=0.10), marginally occurred from baseline to 6 months (F1, 104=3.2,
=0.08), and was significant from 3 to 6 months (F1, 104=6.43,
=0.01).
The overall significant interaction suggests varying responses in the dependent variables between RBAC and placebo over time, which is being driven by systolic blood pressure, as it decreased in the RBAC group, but increased in the placebo group. In addition, CD4
manifested a non-significant increase from baseline to 3 months then decreased from 3 to 6 months in the RBAC group, whereas it decreased at 3 months followed by a slight increase at 6 months in the placebo group. Skin blood flow in response to nitric oxide improved non-significantly overall in both groups, but worsened from 3 to 6 months in the placebo group. Thus, RBAC treatment may contribute to modest short-term improvements in systolic blood pressure, endothelial function, and CD4
cell count, which could help improve the overall health profile of HIV
adults.
Persons with HIV on ART suffer disproportionately from hypertension and endothelial dysfunction compared to the non-infected population, and conventional medical therapy does not alleviate these issues. RBAC is a safe, low-risk alternative that may help to improve the overall quality of life of these patients through modest improvements in these biomarkers plus CD4
cell count.
Este ensayo analiza cómo la creatividad otorga a la conciencia una fuerza renovadora y cómo su poder transformador proviene del nivel inconsciente de la psique, como se explica en la Psicología ...Analítica de Carl Jung y sus seguidores. En particular, se centra en mostrar cómo en el estrato más profundo del inconsciente se genera una creación visionaria que convierte al creador en una especie de medium consumido por un impulso superior a su fuerza. Un impulso, que puede expresarse en una obra artística o exteriorizarse en un brote de locura cuando no se comprende el significado profundo de la experiencia creativa en el self . El artículo también analiza la creación en sus relaciones con el desarrollo humano en el contexto de la Psicología Analítica y su conceptualización como individuación. En ese sentido, destaca cómo, a través de las emociones que una obra de arte consigue despertar en el espectador, el artista logra establecer una comunicación con su público.
Se establece que la mejor definición del autismo se deriva de experiencias vividas por personas con esta condición, por tanto, se ofrecen sus voces, relacionando acciones y expresiones con procesos ...de pensamiento explicados psicológicamente. Creatividad, emoción, comunicación y lenguaje son abordados desde tres personas destacadas, Temple Grandin, John E. Robison y Donna Williams, y son explicados utilizando como fundamento principal la teoría analítica de Carl Jung. Finalmente, el artículo enfoca la relación del arte con el bienestar y resalta su beneficio aplicado a las propuestas terapéuticas y al conocimiento profundo del Sí Mismo, como figura relevante de la psique.
Aim
Treatment‐resistant depression patients are more likely to suffer from comorbid physical and mental disorders, experience marked and protracted functional impairment, and incur higher health‐care ...costs than non‐affected individuals. Magnesium sulfate is a treatment option that may offer great potential for patients with treatment‐resistant depression based on prior work in animals and humans.
Methods
Twelve subjects with mild or moderate treatment‐resistant depression were randomized into a double‐blind crossover trial to receive an infusion of 4 g of magnesium sulfate in 5% dextrose or placebo infusion of 5% dextrose with a 5‐day washout in between the 8‐day intervention period. Subjects were assessed before and after the intervention for serum and urine magnesium, lipid panel, the Hamilton Rating Scale for Depression, and the Patient Health Questionnaire‐9.
Results
We found a difference in serum magnesium from day 2 to 8 (pre‐infusion) (P < 0.002) and from baseline to day 8 (P < 0.02). No changes were noted on the Hamilton Rating Scale for Depression or the Patient Health Questionnaire‐9 24 h post‐treatment, but as serum magnesium increased from baseline to day 7, the Patient Health Questionnaire‐9 decreased from baseline to day 7 (P = 0.02).
Conclusion
Magnesium sulfate did not significantly affect depression 24 h post‐infusion, but other results were consistent with the literature. The association between changes in serum magnesium and the Patient Health Questionnaire‐9 supports the idea that magnesium sulfate may be used to address treatment‐resistant depression, an ongoing medical challenge.
PDF
